Clinical Trial

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

Study acronym: MARINER
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
Protocol Amendment History 1 change
minor Completion pushed: 2026-04-30 -> 2026-12-30 2026-08-14
Trial Details
NCT Number NCT05575037
Lead Sponsor Brigham and Women's Hospital
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Enrollment 17 participants
Start Date 2023-08-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13